FDA Investigator Cheryl A Grandinetti
Cheryl A Grandinetti has inspections in 3 countries as of 02 Feb 2024. Cheryl A Grandinetti has collaborated with a combined 979 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
12
Last Inspection Date:
02 Feb 2024
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America,
Congo,
United Kingdom of Great Britain and Northern Ireland
Co-Investigator(s):
Allen Lou,
Ann B Borromeo,
Byungja E Marciante,
Charles J Chacko,
Christina N Maurino,
Craig A Garmendia,
Craig T Rybus,
Cynthia F Kleppinger, MD,
David L Chon,
Deborah B Nixon,
Denise M Visco, Investigator,
Douglas C Kovacs,
Eileen J Bannerman,
Emmanuel J Ramos,
Eric Rothschild,
Erin D Mccaffery,
Geoffrey K Kilili,
George Pyramides,
Guerlain Ulysse,
Jawaid Hamid,
Jean M Kelahan,
Joan A Loreng,
John Dan,
Joseph F Owens,
Karen E D'orazio,
Kassa Ayalew, MD,
Kent A Conforti,
Lata C Mathew, PhD,
Leon L Crawley,
Liatte Kreuger, PharmD,
Lisa Harlan,
LT Richard A Lyght,
Matthew A Spataro,
Mayar M Mussa,
Melissa T Roy,
Michael Serrano,
Michelle D Haamid,
Nina Yang,
Paul L Bellamy,
Peter R Lenahan,
Regina T Brown,
Robert W Jennings,
Rodney T Allnutt,
Ruth A Williams,
Sereen Gmorgan Murray,
Sheri L Stephenson,
Stephanie T Durso,
Tawny L Colling,
Tonia F Bernard,
Tracy R Ball,
Tyanna N Hadley,
Tynna N Hadley,
Vanessa E Coulter,
William P Tonkins,
Young M Yoon,
Yvesna C Blaise
Cheryl A Grandinetti's Documents
Publish Date | Document Type | Title |
---|---|---|
October, 2019 | FDA 483 | Jan L. Brandes, M.D. - Form 483, 2019-10-18 |
May, 2019 | FDA 483 | SK Life Science Inc. - Form 483, 2019-05-22 |
August, 2019 | FDA 483 | PPD, Inc., part of Thermo Fisher Scientific - Form 483, 2019-08-15 |
July, 2018 | FDA 483 | Catalyst Pharmaceuticals, Inc. - Form 483, 2018-07-27 |
December, 2018 | FDA 483 Response | Novartis Pharmaceuticals Corporation - Form 483R, 2019-01-21 |
December, 2018 | FDA 483 | Novartis Pharmaceuticals Corporation - Form 483, 2018-12-14 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more